-
公开(公告)号：EP2316439B1
公开(公告)日：2015-06-17
申请号：EP10009943.1
申请日：2002-04-30
申请人： EURO-CELTIQUE S.A.
发明人： Tavares, Lino , Reidenberg, Bruce E. , Sackler, Richard S. , Wright, Curtis , Alfonso, Mark A. , Oshlack, Benjamin , Cassidy, James P. , Carpanzano, Anthony E. , Gullapalli, Rampurna Prasad , Shevchuk, Ihor
CPC分类号： A61K9/7023 , A61K9/7084 , A61K9/7092 , B09B3/0075 , B09B2220/14
-
2.发明公开Abuse resistant opioid containing transdermal systems 有权Missbrauchssichere，opioidenthaltende transdermale Systeme
公开(公告)号：EP2316439A1
公开(公告)日：2011-05-04
申请号：EP10009943.1
申请日：2002-04-30
申请人： EURO-CELTIQUE S.A.
发明人： Tavares, Lino , Reidenberg, Bruce E. , Sackler, Richard S. , Wright, Curtis , Alfonso, Mark A. , Oshlack, Benjamin , Cassidy, James P. , Carpanzano, Anthony E. , Gullapalli, Rampurna Prasad , Shevchuk, Ihor
CPC分类号： A61K9/7023 , A61K9/7084 , A61K9/7092 , B09B3/0075 , B09B2220/14
摘要： The present invention relates to transdermal dosage form ( Fig. 1-3 ) comprising at least one activating agent and at least one inactivating agent. The dosage form ( Fig. 1-3 ) releases the inactivating agent upon disruption of the dosage form ( Fig. 1-3 ) thereby preventing or hindering misuse of the active agent contained in the dosage form ( Fig. 1-3 ).
摘要翻译： 本发明涉及包含至少一种活化剂和至少一种灭活剂的透皮剂型（图1-3）。 剂型（图1-3）在剂型破坏时释放灭活剂（图1-3），从而防止或阻碍剂型中包含的活性剂的滥用（图1-3）。
-
3.发明公开Transdermal buprenorphine dosage regimen for analgesia 审中-公开经皮DosierungsschemafürBuprenorphin zur Schmerzstillung
公开(公告)号：EP1913938A1
公开(公告)日：2008-04-23
申请号：EP07022206.2
申请日：2003-12-15
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K9/70 , A61K31/485 , A61P25/04
CPC分类号： A61K9/7023 , A61K31/485
摘要： Dosage regimens of buprenorphine achieving rapid pain relief without increasing nausea, vomiting, or other adverse effects, are described. Also described are buprenorphine dosage regimens for treating chronic pain comprising administering to the patient (1) a first buprenorphine-containing transdermal dosage form for a first dosing period that is no more than about 5 days; (2) a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than 5 days, the second dosage form comprising the same dosage of buprenorphine as, or a greater dosage of buprenorphine than, the first dosage form; and (3) a third buprenorphine-containing transdermal dosage form for a third dosing period, the third dosage form comprising a greater dosage of buprenorphine than the second dosage form.
摘要翻译： 描述了丁丙诺啡在不增加恶心，呕吐或其他副作用的情况下快速缓解疼痛缓解的剂量方案。 还描述了用于治疗慢性疼痛的丁丙诺啡剂量方案，包括向患者施用（1）第一给药期不超过约5天的含有丁丙诺啡的透皮剂型; （2）第二给药期间不超过5天的第二种含丁丙诺啡的透皮剂型，所述第二剂型包含与第一剂型相同的丁丙诺啡剂量或更大剂量的丁丙诺啡; 和（3）第三给药期的含有丁丙诺啡的透皮剂型，所述第三剂型包含比所述第二剂型更大剂量的丁丙诺啡。
-
公开(公告)号：EP2062573B1
公开(公告)日：2011-11-16
申请号：EP08020810.1
申请日：2002-04-30
申请人： EURO-CELTIQUE S.A.
发明人： Tavares, Lino , Reidenberg, Bruce E. , Sackler, Richard S. , Wright, Curtis , Alfonso, Mark A. , Oshlack, Benjamin , Cassidy, James P. , Carpanzano, Anthony E. , Gullapalli, Rampurna Prasad , Shevchuk, Ihor
CPC分类号： A61K9/7023 , A61K9/7084 , A61K9/7092 , B09B3/0075 , B09B2220/14
-
5.发明公开Abuse resistant opioid containing transdermal systems 有权Missbrauchssichere Opioide mit transdermalen系统
公开(公告)号：EP2062573A1
公开(公告)日：2009-05-27
申请号：EP08020810.1
申请日：2002-04-30
申请人： EURO-CELTIQUE S.A.
发明人： Tavares, Lino , Reidenberg, Bruce E. , Sackler, Richard S. , Wright, Curtis , Alfonso, Mark A. , Oshlack, Benjamin , Cassidy, James P. , Carpanzano, Anthony E. , Gullapalli, Rampurna Prasad , Shevchuk, Ihor
CPC分类号： A61K9/7023 , A61K9/7084 , A61K9/7092 , B09B3/0075 , B09B2220/14
摘要： The present invention relates to transdermal dosage form ( Fig. 1-3 ) comprising at least one activating agent and at least one inactivating agent. The dosage form ( Fig. 1-3 ) releases the inactivating agent upon disruption of the dosage form ( Fig. 1-3 ) thereby preventing or hindering misuse of the active agent contained in the dosage form ( Fig. 1-3 ).
摘要翻译： 本发明涉及包含至少一种活化剂和至少一种灭活剂的透皮剂型（图1-3）。 剂型（图1-3）在剂型破坏时释放灭活剂（图1-3），从而防止或阻碍剂型中包含的活性剂的滥用（图1-3）。
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
